PTC Therapeutics Inc (PTCT)
40.41
-0.06
(-0.15%)
USD |
NASDAQ |
Nov 04, 16:00
40.40
-0.02
(-0.04%)
After-Hours: 20:00
PTC Therapeutics Enterprise Value: 2.305B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 2.305B |
| October 31, 2024 | 2.262B |
| October 30, 2024 | 2.319B |
| October 29, 2024 | 2.461B |
| October 28, 2024 | 2.305B |
| October 25, 2024 | 2.326B |
| October 24, 2024 | 2.376B |
| October 23, 2024 | 2.459B |
| October 22, 2024 | 2.216B |
| October 21, 2024 | 2.148B |
| October 18, 2024 | 2.199B |
| October 17, 2024 | 2.038B |
| October 16, 2024 | 2.015B |
| October 15, 2024 | 2.081B |
| October 14, 2024 | 2.202B |
| October 11, 2024 | 2.192B |
| October 10, 2024 | 2.152B |
| October 09, 2024 | 2.264B |
| October 08, 2024 | 2.328B |
| October 07, 2024 | 1.883B |
| October 04, 2024 | 1.892B |
| October 03, 2024 | 1.912B |
| October 02, 2024 | 1.994B |
| October 01, 2024 | 1.965B |
| September 30, 2024 | 2.045B |
| Date | Value |
|---|---|
| September 27, 2024 | 2.081B |
| September 26, 2024 | 2.088B |
| September 25, 2024 | 2.010B |
| September 24, 2024 | 2.001B |
| September 23, 2024 | 2.018B |
| September 20, 2024 | 2.010B |
| September 19, 2024 | 1.973B |
| September 18, 2024 | 1.921B |
| September 17, 2024 | 1.889B |
| September 16, 2024 | 1.789B |
| September 13, 2024 | 1.806B |
| September 12, 2024 | 1.707B |
| September 11, 2024 | 1.674B |
| September 10, 2024 | 1.618B |
| September 09, 2024 | 1.608B |
| September 06, 2024 | 1.618B |
| September 05, 2024 | 1.622B |
| September 04, 2024 | 1.775B |
| September 03, 2024 | 1.762B |
| August 30, 2024 | 1.908B |
| August 29, 2024 | 1.925B |
| August 28, 2024 | 1.898B |
| August 27, 2024 | 1.908B |
| August 26, 2024 | 1.877B |
| August 23, 2024 | 1.818B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.292B
Minimum
Apr 18 2024
4.670B
Maximum
May 22 2023
2.842B
Average
2.870B
Median
Enterprise Value Benchmarks
| Pfizer Inc | 221.03B |
| Vertex Pharmaceuticals Inc | 115.80B |
| BridgeBio Pharma Inc | 6.072B |
| Cassava Sciences Inc | 1.050B |
| Crinetics Pharmaceuticals Inc | 3.674B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -99.18M |
| Revenue (Quarterly) | 186.70M |
| Total Expenses (Quarterly) | 220.06M |
| EPS Diluted (Quarterly) | -1.29 |
| Gross Profit Margin (Quarterly) | 91.68% |
| Profit Margin (Quarterly) | -53.12% |
| Earnings Yield | -15.61% |
| Normalized Earnings Yield | -11.02 |